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A B S T R A C T
Purpose
Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now
standard therapy for patients with lung cancer. The immunosuppressive effect of corticosteroids
may reduce efficacy of PD-(L)1 blockade. On-treatment corticosteroids for treatment of immune-
related adverse events do not seem to affect efficacy, but the potential impact of baseline corti-
costeroids at the time of treatment initiation is unknown. Clinical trials typically excluded patients
who received baseline corticosteroids, which led us to use real-world data to examine the effect of
corticosteroids at treatment initiation.
Methods
We identified patients who were PD-(L)1–naı̈ve with advanced non–small-cell lung cancer from two
institutions—Memorial Sloan Kettering Cancer Center and Gustave Roussy Cancer Center—who
were treated with single-agent PD-(L)1 blockade. Clinical and pharmacy records were reviewed to
identify corticosteroid use at the time of beginning anti–PD-(L)1 therapy.We performedmultivariable
analyses using Cox proportional hazards regression model and logistic regression.
Results
Ninety (14%) of 640 patients treated with single-agent PD-(L)1 blockade received corticosteroids
of$ 10 mg of prednisone equivalent daily at the start of the PD-(L)1 blockade. Common indications
for corticosteroids were dyspnea (33%), fatigue (21%), and brain metastases (19%). In both in-
dependent cohorts, Memorial Sloan Kettering Cancer Center (n = 455) and Gustave Roussy Cancer
Center (n = 185), baseline corticosteroids were associated with decreased overall response rate,
progression-free survival, and overall survival with PD-(L)1 blockade. In amultivariable analysis of the
pooled population, adjusting for smoking history, performance status, and history of brain me-
tastases, baseline corticosteroids remained significantly associated with decreased progression-
free survival (hazard ratio, 1.3; P = .03), and overall survival (hazard ratio, 1.7; P , .001).
Conclusion
Baseline corticosteroid use of $ 10 mg of prednisone equivalent was associated with poorer
outcome in patients with non–small-cell lung cancer who were treated with PD-(L)1 blockade.
Prudent use of corticosteroids at the time of initiating PD-(L)1 blockade is recommended.
J Clin Oncol 36:2872-2878. © 2018 by American Society of Clinical Oncology
INTRODUCTION
The development of immune checkpoint block-
ade (ICB) therapy has dramatically changed
the treatment landscape for patients with cancer.1
For patients with advanced non–small-cell
lung cancer (NSCLC), treatment with anti-
programmed cell death 1 (PD-1) or programmed
death-ligand 1 (PD-L1) therapy (PD-(L)1
blockade) is now a standard of care.2-4 As real-
world clinical experience with ICB agents con-
tinues to grow, new questions have emerged re-
garding the treatment of patients that could not
be answered in the initial groundbreaking clinical
trials.
Corticosteroids are commonly used in pa-
tients with NSCLC to treat a variety of indications,
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including fatigue, dyspnea, decreased appetite, and symptomatic
brain metastases.5-9 Given the immunosuppressive properties of
corticosteroids and the potential effect on T-cell function,10 there is
understandable concern that the use of these agents could decrease
the efficacy of ICB. As a result, use of corticosteroids before the
start of therapy has been a uniform exclusion criterion in clinical
trials of ICB. It is perhaps surprising, but reassuring, to see
emerging data that on-treatment corticosteroids used for the
management of immune-related adverse events11 do not seem to
negatively affect efficacy.12-15 Yet there are no data to date that
evaluate whether corticosteroids at baseline affect the efficacy of
ICB. We therefore evaluated the potential impact of systemic
corticosteroids at the start of ICB on the efficacy of PD-(L)1
blockade in more than 600 patients who were treated at two in-
dependent cancer centers.
METHODS
Patients
Patients with advanced NSCLC who were treated with single-agent
PD-(L)1 inhibitor (pembrolizumab, nivolumab, atezolizumab, or dur-
valumab) with treatment initiation between April 2011 to September 2017
were identified atMemorial Sloan Kettering Cancer (MSKCC; n = 455) and
Gustave Roussy Cancer Center (GRCC; n = 185). Patients’ records, in-
cluding pharmacy records, were reviewed to determine if patients were
documented as having received any oral or intravenous corticosteroids on
the day PD-(L)1 blockade was started. Use of corticosteroids within 30 days
of the start of PD-(L)1 blockade was also collected for the MSKCC cohort.
Information about the type of corticosteroid, indication, and route of
administration were collected. Dose of corticosteroids was expressed as
total daily milligrams of prednisone equivalents. Clinicopathologic
characteristics, including age, gender, histology, Eastern Cooperative
Oncology Group performance status, and smoking history, were collected
for all patients. Efficacy of PD-(L)1 blockade was determined by local
specialized radiologists (C.C. at GRCC andN.L., A.P., and D.H. atMSKCC)
using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
All patients were observed until death or data lock—March 2017 for
MSKCC and December 2017 for GRCC.
Statistical Analysis
Patient characteristics were described according to the status of
corticosteroid use at baseline and compared with Fisher’s exact test or x2
test for categorical data. Progression-free survival (PFS) was defined as the
time from ICB initiation to the first event (tumor progression or death
from any cause); overall survival (OS) was defined as the time from ICB
initiation to death from any cause. Patients with no event were censored at
the date of last follow-up. Best overall response differences were analyzed
using Fisher’s exact test or x2 test. Patients who died before radiologic
assessment were categorized as nonresponders. Other patients who were
not evaluable for response (n = 4 inMSKCC cohort, none in GRCC cohort),
were not included in objective response assessment but were included for
PFS and OS. Survival curves were estimated using the Kaplan-Meier
method and compared with the log-rank test (univariable analysis).
Univariable hazard ratios (HRs) were calculated using the log-rank
method. We used multivariable Cox proportional hazards regression
model to determine HRs and 95% CIs for PFS and OS and odds ratios for
best overall response. The pooled cohort (N = 640) was used in subgroup
and multivariable analysis to increase power. Statistical tests were two
sided, and P values, .05 were considered statistically significant. Statistical
analyses were carried out using R statistical software.
RESULTS
We identified 640 patients treated with PD-(L)1 blockade at
MSKCC (n = 455) and GRCC (n = 185). At the time of ICB
initiation, 90 (14%) of the 640 patients received $ 10 mg of
prednisone equivalent—53 (12%) of 455 patients in the MSKCC
cohort and 37 (20%) of 185 patients in the GRCC cohort. A small
fraction of additional patients (n = 17; 3%) received , 10 mg of
prednisone equivalent at the initiation of ICB and were included in
the noncorticosteroid group, as this low dose was considered to be
in the range of physiologic adrenal replacement and is not typically
excluded in clinical trials. The most common indications for
corticosteroids were dyspnea or other respiratory symptoms
(33%), fatigue (21%), and brain metastases (19%; Appendix Table
A1, online only). In each group, clinicopathologic characteristics
were typical of patients with advanced NSCLC and were generally
well balanced between those who did or did not receive cortico-
steroids, with the two expected exceptions; poor performance
status and history of brain metastases were more common in those
who received corticosteroids (Table 1).
In the MSKCC cohort, use of baseline corticosteroids of
$ 10mg was associated with decreased overall response rate (ORR;
6% v 19%; P = .02; Fig 1A), shorter PFS (median, 1.9 months v
2.6 months; HR, 1.7; P = .001; Fig 1B), and shorter OS (median,
5.4months v 12.1 months; HR, 2.1; P, .001; Fig 1C). In the GRCC
cohort, ORR was decreased but not significantly different in those
who received baseline corticosteroids $ 10 mg (8% v 18%; P = .2;
Fig 1D), whereas PFS and OS were significantly shorter (PFS:
median, 1.7 months v 1.8 months; HR, 1.5; P , .001; Fig 1E; and
OS: median, 3.3 months v 9.4 months; HR, 2.0; P , .001; Fig 1F).
In the pooled cohort of patients from both centers (N = 640),
baseline corticosteroids had a consistently negative effect on ef-
ficacy of PD-(L)1 blockade (Appendix Fig A1, online only), with
diminished PFS and OS observed in nearly every subgroup ex-
amined (Fig 2).
Cognizant of the potential confounding effects of prognostic
variables associated with corticosteroid use and other predictive
features associated with response to PD(L)-1 blockade, we per-
formed a multivariable analysis in the pooled cohort (N = 640),
incorporating smoking history, performance status, and history of
brain metastases. Corticosteroid use ($ 10 mg v , 10 mg) at the
time of the initiation of PD-(L)1 blockade remained associated
with decreased ORR (odds ratio, 0.42; P = .053) and significantly
shorter PFS (HR, 1.31; P = .03) and OS (HR, 1.66; P , .001;
Table 2).
We also examined the effect of corticosteroid dose and timing
on efficacy. In the pooled cohort from both centers, there was
a similar detriment in efficacy when examining . 20 mg of
prednisone or 10 mg to 19 mg compared with patients who re-
ceived, 10 mg of corticosteroids (Appendix Fig A2, online only).
In the MSKCC cohort (data not available from GRCC cohort),
patients who received and discontinued corticosteroids days 1 to 30
before to the initiation of PD-(L)1 (66 of 455 patients) had in-
termediate PFS and OS compared with those who received cor-
ticosteroids on the day of ICB initiation (53 of 455 patients) and
those who received no corticosteroids within 30 days of the start of
therapy (Appendix Fig A3, online only).
jco.org © 2018 by American Society of Clinical Oncology 2873
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Six patients (MSKCC [n = 3], GRCC [n = 3]) experienced
a partial response to PD-(L)1 blockade despite the use of corti-
costeroids at the time of treatment initiation (Appendix Table A2,
online only). These patients received 10 mg to 20 mg of corti-
costeroids for palliative indications, such as fatigue, respiratory
symptoms, and pain. There were no evident differences in the
clinical features of patients who experienced responses; all re-
sponders had an Eastern Cooperative Oncology Group perfor-
mance status of 1. Four of six patients had continued response to
therapy for more than 15 months, although the responses of two
patients were more limited, including one patient whose response
lasted for only 2.4 months and was followed by rapid clinical
deterioration and death as a result of progressive disease.
DISCUSSION
We report that the use of corticosteroids at the start of PD-(L)1
blockade is associated with inferior outcomes in two independent
cohorts. This analysis of 640 patients from two institutions
evaluated a patient population that was largely excluded from
clinical trials that evaluated PD-(L)1 blockade such that this can
only be addressed with real-world data.
Corticosteroids, specifically systemic adrenal glucocorticoids,
play a critical physiologic role in feedback inhibition of in-
flammatory responses and immune system homeostasis and have
long been used for their immunosuppressive properties. These
effects can offer significant benefit in the treatment of autoimmune
diseases, but may have unintended consequences in patients with
cancer. Exogenous dexamethasone has been demonstrated to
suppress IL-2–mediated activation of effector T cells16 and increase
immunosuppressive regulatory T cells.17,18
Corticosteroids are the mainstay for the treatment of
immune-related adverse events in patients who receive ICB
therapy, and fortunately the use of corticosteroids in patients with
melanoma13,14 and NSCLC12 (and other immune modulating
medications, such as infliximab) in this context has not been
associated with decreased efficacy of ICB. Still, it is possible that
treatment with corticosteroids immediately before the initiation of
PD-(L)1 blockade could distinctly affect efficacy, perhaps by
blunting a proliferative burst of CD8-positive T cells needed in
response to PD-(L)1 blockade.19
Corticosteroids are an important and common treatment of
a variety of symptoms in patients with cancer, particularly NSCLC.
Corticosteroids may be required for the control of brain metastasis
and can improve symptoms of fatigue, dyspnea,9 and anorexia.
On the basis of these data, in patients for whom treatment with
PD-(L)1 blockade is planned, it may be prudent to attempt to
manage these symptoms with other pharmacologic9,20,21 and/or
nonpharmacologic8,22 methods. These strategies could enable
patients to be tapered off corticosteroids before the start of PD-(L)1
blockade to potentially achieve maximum benefit from these
agents; however, of importance, medically necessary corticoste-
roids (eg, management of brain metastases) should not be avoided.
This work has focused on patients who were treated with
single-agent PD-(L)1 inhibitor. Of note, regimens that combine
Table 1. Baseline Patient Characteristics of the Memorial Sloan Kettering Cancer Center and Gustave Roussy Cancer Center Cohorts
Baseline Characteristic
MSKCC GRCC
Prednisone $ 10 mg
(n = 53)
Prednisone , 10 mg
(n = 402) P
Prednisone $ 10 mg
(n = 37)
Prednisone ,10 mg
(n = 148) P
Age, years
$ 65 60 (32) 55 (221) .55 35 (13) 39 (57) .9
, 65 40 (21) 45 (181) 65 (24) 61 (91)
Sex
Male 49 (26) 48 (194) 1.0 70 (26) 65 (96) .6
Female 51 (27) 52 (208) 30 (11) 35 (52)
ECOG performance status
0-1 70 (37) 92 (369) , .01 57 (21) 83 (123) , .01
$ 2 30 (16) 8 (33) 43 (16) 17 (25)
Smoking status
Ever 77 (41) 83 (335) .3 92 (34) 87 (129) .8
Never 22 (12) 17 (67) 8 (3) 11 (16)
Histology
Squamous 15 (8) 18 (72) .7 24 (9) 28 (40) .8
Nonsquamous 85 (45) 82 (330) 76 (28) 73 (108)
EGFR mutation status
EGFR mutant 11 (6) 8 (32) .4 5 (2) 5 (7) .7
EGFR wild type 77 (41) 83 (333) 62 (23) 70 (104)
EGFR unknown 11 (6) 9 (37) 32(12) 25 (37)
Line of therapy
First or second line 56 (30) 67 (268) .2 38 (14) 52 (78) .1
Third line or later 46 (23) 33 (134) 62 (23) 47 (70)
History of brain metastases
Yes 42 (22) 23 (94) , .01 51 (19) 13 (19) , .01
No 58 (31) 77 (308) 49 (18) 87 (129)
NOTE. Data are given as No. (%).
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; GRCC, Gustave Roussy Cancer Center; MSKCC, Memorial Sloan
Kettering Cancer Center.
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Fig 1. Response rates (A and D), progression-free survival (PFS; B and E), and overall survival (OS; C and E) of patients treated with programmed death-ligand 1 blockade
on the basis of reported corticosteroid usage atMemorial Sloan Kettering Cancer Center (MSKCC; A-C) and Gustave Roussy Cancer Center (GRCC; D-F). Four hundred fifty-
one of 455 patients were evaluable for response in the MSKCC cohort (A) and 185 of 185 patients were evaluable for response in the GRCC cohort (D). CR, complete
response; POD, progression of disease; PR, partial response; SD, stable disease.
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chemotherapy and PD-(L)1 blockade23 are emerging with
promising efficacy, despite the routine use of corticosteroids as
a supportive medication for the prevention of rash, nausea, and
potential hypersensitivity reactions. It is possible that transient
corticosteroids given along with chemotherapy and PD-(L)1
blockade are not deleterious in the same way as more chronically
administered corticosteroids leading up to PD-(L)1 blockade.
Alternatively, the efficacy of these regimens despite corticosteroid
administration could be a signal of synergy between chemotherapy
and ICB, overcoming the otherwise deleterious effects of con-
current steroids. It will be interesting to examine the outcomes of
chemotherapy plus PD(L)-1 combinations that minimize corti-
costeroid use—for example, use of abraxane in the IMpower130
(ClinicalTrial.gov identifier: NCT 02367794)24 and KEYNOTE-
407 (ClinicalTrials.gov identifier: NCT 02775435)25 studies.
Although data on the effects of baseline corticosteroids is only
possible through such real-world studies as this, there are im-
portant limitations. Although outcomes were assessed retrospec-
tively, objective response was determined by direct review of scans
by radiologists and quantified by RECIST. The overall sample size is
large (N = 640), but only a modest number of patients received
corticosteroids of any dose at the time of ICB initiation (n = 107),
which may reflect the caution of clinical providers in administering
corticosteroids to patients being treated with ICB. A pooled
analysis of both independent cohorts was used in subgroup and
multivariable analyses to increase power; however, this sample size
limited the comprehensive exploration of varying cut points of
dose or timing of corticosteroids associated with distinctly inferior
outcomes. The prednisone threshold of 10 mg was chosen here as it
is typically applied as an exclusion in clinical trials, and we found
A
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Fig 2. Forest plot of subgroup analyses of
independent prognostic factors for (A) pro-
gression-free survival and (B) overall survival
in the pooled cohort (Memorial Sloan Ket-
tering Cancer Center and Gustave Roussy
Cancer Center combined). ECOG, Eastern
Cooperative Oncology Group; HR, hazard
ratio; PS, performance status.
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similar detrimental effects in patients who received 10 mg to 19 mg
daily versus $ 20 mg of prednisone.
An additional limitation of this work is distinguishing be-
tween the prognostic and predictive effects of corticosteroids in
patients who receive ICB. Use of corticosteroids may simply
identify patients with aggressive disease and greater symptom
burden necessitating their use. Given the persistent deleterious
effect of corticosteroids in both the subgroup and multivariable
analyses, we propose that baseline corticosteroids have a predictive
effect, but we do not have functional or mechanistic data to prove
this with certainty. In addition, data on the known predictive
biomarkers, such as PD-L1 staining and tumor mutational burden,
were not available in the majority of patients in this analysis and so
could not be included here. We propose that baseline corticosteroid
use should be incorporated in future data analyses to further
optimize predictive models of PD-(L)1 efficacy. Ultimately,
whether baseline corticosteroids represent correlation or causa-
tion, it is clinically relevant for both patients and providers to
recognize the effect of corticosteroids on ICB efficacy in patients
with NSCLC.
Treatment with PD-(L)1 blockade has been a significant
advance for patients with NSCLC and other malignancies. As these
agents have become a standard of care, it is imperative that we
recognize and inform common practices that may affect the ef-
ficacy of these agents. The administration of corticosteroids for
a variety of indications, from decreased appetite and fatigue to
symptomatic brain metastases, is one such common practice. We
have demonstrated that the use of corticosteroids at the time of the
initiation of PD-(L)1 blockade is associated with diminished ef-
ficacy of ICB. Prudent use of corticosteroids at the time of initiating
PD-(L)1 blockade is warranted.
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Fig A1. (A) Response rates of patients treated with programmed cell death-1 and programmed death-ligand 1 blockade according to different doses of corticosteroids in
the pooled cohort of patients fromMemorial Sloan Kettering Cancer Center (MSKCC) and Gustave Roussy Cancer Center (GRCC; n = 636; four patients fromMSKCCwere
not evaluable for response). (B) Progression-free survival (PFS) and (C) overall survival (OS) of patients treated with PD-(L)1 blockade according to different doses of
corticosteroids in the pooled cohort of patients fromMSKCC and GRCC cohorts (N = 640). CR, complete response; POD, progression of disease; PR, partial response; SD,
stable disease.
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Fig A2. (A) Response rates of patients treated with programmed cell death-1 and programmed death-ligand 1 blockade according to different doses of corticosteroids in
the pooled cohort of patients fromMemorial Sloan Kettering Cancer Center (MSKCC) and Gustave Roussy Cancer Center (GRCC; n = 636; four patients fromMSKCCwere
not evaluable for response). (B) Progression-free survival (PFS) and (C) overall survival (OS) of patients treated with PD-(L)1 blockade according to different doses of
corticosteroids in the pooled cohort of patients fromMSKCC and GRCC cohorts (N = 640). CR, complete response; POD, progression of disease; PR, partial response; SD,
stable disease.
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Fig A3. (A) Response rates (n = 451), (B) progression-free survival (PFS), and (C) overall survival (OS) of patients treated programmed cell death-1 and programmed death-
ligand 1 blockade according to time at which corticosteroids were administered in the 30 days before immune checkpoint blockade (ICB) initiation (Memorial Sloan
Kettering Cancer Center). CR, complete response; POD, progression of disease; PR, partial response; SD, stable disease.
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Table A2. Clinical Features of Patients on Baseline Corticosteroids With Response to Programmed Death-Ligand 1 Blockade
Patient
Age,
Years Sex
ECOG
PS
Smoking History
(pack-years)
Indication for
Corticosteroid Use
Corticosteroid Dose
(prednisone equivalent), mg
Duration of Corticosteroids
Before ICB, Weeks
Duration of Response,
Months
MSKCC 1 54.0 M 1 Former (29.0) Fatigue 10.0 8.0 18.0 (ongoing)
MSKCC 2 47.0 F 1 Never Fatigue 20.0 3.0 6.0
MSKCC 3 76.0 M 1 Never Fatigue 10.0 10.0 25.0
GRCC 1 74.0 M 1 Former (15.0) Dyspnea 10.0 Unknown 12.0
GRCC 2 73.0 M 1 Former (10.0) Dyspnea and pain 20.0 Unknown 31.0 (ongoing)
GRCC 3 62.0 F 1 Former (50.0) Dyspnea and pain 20.0 Unknown 2.4
Abbreviations: ECOG, Eastern Cooperative Oncology Group; F, female; GRCC, Gustave Roussy Cancer Center; ICB, immune checkpoint blockade; M, male; MSKCC,
Memorial Sloan Kettering Cancer Center; PS, performance status.
Table A1. Patient Characteristics and Corticosteroid Indications of Patients in theMemorial Sloan Kettering Cancer Center and Gustave Roussy Cancer Center Cohorts
Baseline Characteristic
MSKCC
(n = 455)
GRCC
(n = 185)
Age, years, median (range) 66 (31-93) 61 (29-84)
Sex
Male 48 (220) 66 (122)
Female 52 (235) 44 (63)
ECOG performance status
0 19 (86) 12 (22)
1 70 (320) 66 (122)
$ 2 11 (49) 22 (41)
Smoking status
Ever 376 87 (161)
Never 79 10 (19)
Pack-years, median (range) 30 (1-190) 37 (3-100)
Histology
Adenocarcinoma 76 (347) 63 (116)
Squamous 18 (80) 26 (49)
NSCLC-other 6 (28) 11 (20)
EGFR mutation status
EGFR mutant 8 (38) 5 (9)
EGFR wild type 82 (374) 69 (127)
EGFR status unknown 9 (43) 26 (49)
Daily dose of corticosteroids (prednisone or equivalent), mg
$ 20 6 (29) 16 (29)
10-19 5 (24) 4 (8)
1-9 2 (10) 4 (7)
0 86 (392) 76 (141)
Median daily dose of corticosteroids (prednisone or
equivalent), mg (range)
13 (3-80) 20 (3-325)
Indication for corticosteroid use $ 10 mg (n = 53) (n = 37)
Dyspnea 30 (15) 41 (15)
Fatigue 33 (18) 3 (1)
Brain metastases 13 (7) 27 (10)
Pain 9 (5) 11 (6)
Other 15 (8) 14 (5)
NOTE. Data are given as No. (%), unless otherwise indicated.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; GRCC, Gustave Roussy Cancer Center; MSKCC,Memorial Sloan
Kettering Cancer Center; NSCLC, non–small-cell lung cancer.
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